Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Atopic Dermatitis Clinical Trials Market

Atopic Dermatitis Clinical Trials Market Trends

  • Report ID: GMI8508
  • Published Date: Mar 2024
  • Report Format: PDF

Atopic Dermatitis Clinical Trials Market Trends

  • The rising incidence and prevalence rates of atopic dermatitis worldwide drive the demand for clinical trials to develop effective treatments to address the growing burden of the disease. For instance, as per the Global Burden of Disease (GBD 2022), about 223 million people were affected with atopic dermatitis, of which around 43 million are aged 1 to 4.
  • Such increasing number of patients necessitate the development of effective therapies, thereby fostering the growth of market.
  • Furthermore, increased awareness of the socioeconomic burden of atopic dermatitis prompts heightened investment from pharmaceutical companies, biotechnology firms, government agencies, and venture capital investors in research and development activities and clinical trials.
  • Moreover, the expanding pipeline of treatments for atopic dermatitis is a key driving force in the clinical trials market due to the increasing number of clinical trials to test these diverse therapeutic approaches, further fostering the market expansion.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global atopic dermatitis clinical trials industry was valued at USD 2.4 billion in 2023 and will exhibit growth at 11.4% to reach USD 6.4 billion by 2032, driven by the rising prevalence of atopic dermatitis.

The outsourced segment accounted for majority of revenue share in 2023 and is expected to reach USD 3.9 billion by 2032, backed by the increased demand for novel treatment, the wider adoption of CROs, and access to specialized expertise.

North America atopic dermatitis clinical trials market accounted for USD 945.8 million in 2023 and is anticipated to record a CAGR of 10.8% through 2032, as the region possesses a robust research infrastructure with leading academic institutions, medical centers, and pharmaceutical companies.

BIOCYTOGEN, Charles River Laboratories, Hooke Laboratories, LLC, Imavita, Novotech, Oncodesign services, QIMA LTD., Redoxis, REPROCELL Inc., and Syneos Health.

Atopic Dermatitis Clinical Trials Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 296
  • Countries covered: 19
  • Pages: 165
 Download Free Sample